Text Size

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze (LVPK)

This study has been completed.
Sponsor:
Information provided by:
Protherics
ClinicalTrials.gov Identifier:
NCT00634504
First received: March 6, 2008
Last updated: January 19, 2010
Last verified: January 2010
History of Changes
  Purpose

The purpose of this study is to investigate whether the administration of Voraxaze reduces exposure to leucovorin and its active metabolite to below the level achieved in patients who have not received Voraxaze.


Condition Intervention Phase
Osteosarcoma
Leukemia
Lymphoma
 Drug: glucarpidase, high-dose methotrexate, leucovorin
Drug: high-dose methotrexate, leucovorin
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment

Resource links provided by NLM:

MedlinePlus related topics: Leukemia Lymphoma
U.S. FDA Resources

Further study details as provided by Protherics:

Primary Outcome Measures:
  • Pharmacokinetics (PK) of leucovorin [ Time Frame: Up to 3 hours after leucovorin ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pharmacokinetics (PK) of methotrexate [ Time Frame: Up to 3 hours after leucovorin ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: May 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
High-dose methotrexate, leucovorin, and Voraxaze
 Drug: glucarpidase, high-dose methotrexate, leucovorin
single intravenous dose
Other Names:
  • Voraxaze, carboxypeptidase G2, CPG2
  • HDMTX, LV
Active Comparator: B
High-dose methotrexate and leucovorin without Voraxaze
 Drug: high-dose methotrexate, leucovorin
standard of care, leucovorin every 6 hours
Other Name: HDMTX, LV

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Receiving High-dose methotrexate (HDMTX) with or without risk of methotrexate (MTX) toxicity, impaired renal function, and delayed MTX elimination
  • Require intravenous leucovorin

Exclusion Criteria:

  • Arm A only: allergic reactions to lactose
  • Arm A only: hereditary fructose or galactose intolerance
  • Arm B only: delayed elimination of MTX
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00634504

  Show 25 Study Locations
Sponsors and Collaborators
Protherics
Investigators
Study Chair: Andrew Saunders, MD
Study Director: Suzanne Kincaid, CCRA Protherics
  More Information

No publications provided

Responsible Party: Suzanne Kincaid, Clinical Project Manager, Protherics
ClinicalTrials.gov Identifier: NCT00634504     History of Changes
Other Study ID Numbers: PR001-CLN-pro017
Study First Received: March 6, 2008
Last Updated: January 19, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Protherics:
high dose methotrexate
Voraxaze
leucovorin
delayed elimination
 methotrexate toxicity
rescue
renal insufficiency

Additional relevant MeSH terms:
Leukemia
Lymphoma
Osteosarcoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Sarcoma
Leucovorin
Levoleucovorin
 Methotrexate
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antidotes
Protective Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Therapeutic Uses
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on May 21, 2013